Clear Street raised the firm’s price target on Krystal Biotech (KRYS) to $288 from $217 and keeps a Buy rating on the shares. The firm says KB407 successfully induced wild-type CFTR protein expression in patient lung epithelial cells, at levels that are expected to be therapeutically meaningful.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Early Proof-of-Concept and Platform Potential Drive Buy Rating on Krystal Biotech Despite Pending Lung Function Data
- Krystal Biotech advances KB407 with positive CF trial data
- Krystal Biotech announces interim update from highest dose cohort of CORAL-1
- Krystal Biotech price target raised to $272 from $255 at BofA
- Krystal Biotech upgraded to Buy from Neutral at Citi